(VIANEWS) – Shares of PHARMING GROUP (AEX-Index: PHARM.AS) rose by a staggering 16.44% in 5 sessions from €1.02 to €1.19 at 17:08 EST on Wednesday, after five consecutive sessions in a row of gains. AEX-Index is sliding 0.04% to €748.07, following the last session’s downward trend.
About PHARMING GROUP
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Earnings Per Share
As for profitability, PHARMING GROUP has a trailing twelve months EPS of €0.02.
PE Ratio
PHARMING GROUP has a trailing twelve months price to earnings ratio of 59.5. Meaning, the purchaser of the share is investing €59.5 for every euro of annual earnings.
Volatility
PHARMING GROUP’s last week, last month’s, and last quarter’s current intraday variation average was 3.01%, 0.05%, and 2.46%.
PHARMING GROUP’s highest amplitude of average volatility was 3.01% (last week), 1.59% (last month), and 2.46% (last quarter).
More news about PHARMING GROUP (PHARM.AS).
